Is HRMY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on WAKIX is still accelerating in year seven, with revenue (ttm) at ~$959.9M, all from WAKIX. The bear case rests on one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. Analysts covering it are spread from $30.00 to $70.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $30.00, -21.3% from the $38.12 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

WAKIX is still accelerating in year seven. Second-quarter net product revenue of ~$261.3M grew 30% year over year, and average patients rose by ~450 in the quarter, the second-largest quarterly patient gain the company has reported. The most optimistic analyst target on HRMY is $70.00, +83.6% from the $38.12 price. That figure is only reachable if this thesis works close to its best case.

One product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical. The seventh filer, AET Pharma US, is still litigating in the District of Delaware; a bench trial concluded in February 2026, post-trial briefing is complete, and closing arguments are set for October 22, 2026, with an adverse ruling capable of pulling that date forward. Harmony and Novitium filed a separate infringement suit against AET and its marketing partner Sandoz in April 2026 over the amorphous pitolisant patent (case 26-cv-00453-JLH), and the defendants answered in June with antitrust counterclaims, which introduces a liability the company was not previously carrying. Competitively, the oral orexin agonists in late-stage development at Takeda and Alkermes target the underlying deficiency in narcolepsy type 1 rather than the symptom, and if they reach the market with strong efficacy they could compress WAKIX before its patents expire. Two smaller items are worth noting: gross margin fell from 81.0% to 75.8% year over year on new Novitium royalties, and the CFO departed in July 2026 with an interim officer in place while the search runs. The most pessimistic published target is $30.00, -21.3% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Commercial-stage rare-neurology company whose sole product, WAKIX (pitolisant), treats narcolepsy, backed by a next-generation pitolisant and orexin pipeline.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (WAKIX is still accelerating in year seven) stalling in the reported numbers rather than in the narrative, the risk above (one product carries the entire company, and its exclusivity has a date on it: WAKIX runs to March 2030 including the pediatric extension, and six of the seven ANDA filers (Lupin, Novugen, Novitium, Hikma, Annora and MSN) have already settled to license dates in 2030, which makes generic entry scheduled rather than hypothetical) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

One commercial product: WAKIX (pitolisant), a histamine H3 receptor antagonist and inverse agonist approved for excessive daytime sleepiness and cataplexy in narcolepsy, in adults and in children six and older. It is the only approved narcolepsy therapy that is not a scheduled controlled substance. All of the company's ~$959.9M in trailing revenue comes from it, and all of it is earned in the United States.

Yes, and substantially so. Trailing twelve-month net income is ~$181.3M on ~$959.9M of revenue, and the second quarter of 2026 alone produced ~$75.4M of net income, or ~$1.28 per diluted share, on ~$89.3M of operating income. First-half operating cash flow was ~$120.2M. That separates Harmony from most companies filed under the biotech label, which are cash-burning and pre-revenue.

Harmony's disclosed position is that its IP estate supports WAKIX exclusivity to March 2030, inclusive of a six-month pediatric exclusivity extension it expects to earn on completion of the TEMPO study in Prader-Willi syndrome. Six of the seven generic filers have settled to license dates in 2030, mostly July 2030 if pediatric exclusivity is granted, with Hikma licensed from March 2030. The company argues that later-filed formulation patents could protect parts of the franchise into the 2040s, but those apply to next-generation products rather than the tablet selling today.